Table 1:
Baboon Number |
Maintenance IS therapy | Survival (days) | Cause for euthanasia |
---|---|---|---|
Long survival group | |||
B10815 | Anti-CD40mAb-based | 90 | AHXR |
B9313 | Anti-CD40mAb-based | 136 | Systemic Infection |
B17315 | Anti-CD40mAb-based | 237 | Systemic Infection |
B17615 | Anti-CD40mAb-based | 260 | Systemic Infection |
Short survival group | |||
B17415 | Anti-CD40mAb-based | 12 | AHXR |
B3115 | Anti-CD40mAb-based | 4 | Acute gastric dilatation |
B14214 | Conventional therapy* | 32 | AHXR |
B5415 | Conventional therapy* | 15 | AHXR |
B15815 | Conventional therapy* | 12 | AHXR |
B9015 | Conventional therapy* | 13 | AHXR |
B14115 | Conventional therapy* | 1 | Hyperacute rejection |
Conventional therapy consisted of only FDA-approved agents (various combinations of CTLA4-Ig, tacrolimus, rapamycin, mycophenolate mofetil).
AHXR = acute humoral xenograft rejection.